Aradigm Corporation (NASDAQ:ARDM) released its earnings results on Thursday. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.37, Bloomberg Earnings reports. Aradigm Corporation had a negative return on equity of 665.03% and a negative net margin of 1,515.94%. The firm had revenue of $7.68 million during the quarter.

Shares of Aradigm Corporation (NASDAQ:ARDM) traded up 6.8779% on Friday, hitting $1.4001. The stock had a trading volume of 131,850 shares. Aradigm Corporation has a 1-year low of $0.78 and a 1-year high of $7.19. The company’s market capitalization is $20.73 million. The firm has a 50-day moving average of $1.34 and a 200 day moving average of $1.52.

Separately, Zacks Investment Research cut Aradigm Corporation from a “hold” rating to a “sell” rating in a research note on Tuesday, May 23rd.

TRADEMARK VIOLATION NOTICE: “Aradigm Corporation (ARDM) Issues Quarterly Earnings Results” was originally published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at

Aradigm Corporation Company Profile

Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of products for the treatment and prevention of severe respiratory diseases. The Company’s lead product candidate is Pulmaquin inhaled ciprofloxacin, which is in Phase III clinical trials. It offers AERx pulmonary drug delivery platform and other technologies.

Earnings History for Aradigm Corporation (NASDAQ:ARDM)

Receive News & Ratings for Aradigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aradigm Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.